Detection of metastatic bone lesions in patients with prostate carcinoma 99tcm-monoclonal antibody imaging

Basit Öğe Kaydı
dc.contributor.authorKiraÇ S.
dc.contributor.authorDuman Y.
dc.contributor.authorCÜreklibatur I.
dc.contributor.authorYÜksel D.
dc.contributor.authorNazli O.
dc.contributor.authorGÜnaydin G.
dc.contributor.authorTaner M.
dc.date.accessioned2019-10-27T00:32:30Z
dc.date.available2019-10-27T00:32:30Z
dc.date.issued1997
dc.departmentEge Üniversitesien_US
dc.description.abstractBone scintigraphy has been shown to be sensitive in determining bone involvement in patients with malignancy, but it does not allow the assessment of bone marrow lesions in early disease. The aim of this study was to detect bone marrow invasion using 99Tcm-labelled monoclonal antigranulocyte antibody (AgMoAb) in patients with prostate carcinoma. We studied 56 patients whose mean (± S.D.) age was 67 ± 7 years. The mean prostate-specific antigen level was 6.1 ng ml-1 (normal range 0-5 ng ml 1). Twelve patients were in stage A, 16 in stage B, 17 in stage C and 11 in stage D. Six patients had been receiving chemotherapy and four patients radiotherapy before scanning. Bone scans were obtained 2 h after the intravenous injection of 555 MBq 99Tcm-methylene diphosphonate (99Tcm-MDP). Within a week, bone marrow imaging was performed 4 and 24 h after the injection of 555 MBq 99Tcm-AgMoAb. Metastatic bone lesions were detected on the 99Tcm-MDP scans of 14/56 (25%) patients, of whom one was in stage A, two in stage B, four in stage C and seven in stage D. Hypoactive lesions in bone marrow were detected in 25/56 (45%) patients, of whom two were in stage A, five in stage B, seven in stage C and 11 in stage D. Bone marrow metastases were confirmed in six patients by computed tomography (CT) and magnetic resonance imaging (MRI) and in two patients by marrow aspiration biopsy. A false-positive immune scintigram was found in three patients previously receiving radiotherapy or chemotherapy. We suggest that 99Tcm-AgMoAb scintigraphy is a sensitive procedure for the detection of bone marrow lesions. However, the reason for false-positive and false-negative results should be considered and CT, MRI and marrow biopsy should be performed when clinically necessary. © 1997 Chapman and Hall Ltd.en_US
dc.identifier.doi10.1097/00006231-199710000-00013en_US
dc.identifier.endpage973en_US
dc.identifier.issn0143-3636
dc.identifier.issue10en_US
dc.identifier.pmid9392800en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage968en_US
dc.identifier.urihttps://doi.org/10.1097/00006231-199710000-00013
dc.identifier.urihttps://hdl.handle.net/11454/23805
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofNuclear Medicine Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleDetection of metastatic bone lesions in patients with prostate carcinoma 99tcm-monoclonal antibody imagingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu